The Yb(OTf)3-catalyzed [3+2] cycloaddition of donor–acceptorcyclopropanes with thiourea offers an efficient route to diverse 2-amino-4,5-dihydrothiophenes (up to 92% yield), in which optically active 2-amino-dihydrothiophenes can be produced from enantiomerically pure cyclopropanes. Thiourea, which is an odorless and cheap reagent, provides a CS double bond, serves as an amino source, and functions
Chiusoli, Gian Paolo; Costa, Mirco; Pergreffi, Paola, Gazzetta Chimica Italiana, 1985, vol. 115, # 12, p. 691 - 696
作者:Chiusoli, Gian Paolo、Costa, Mirco、Pergreffi, Paola、Reverberi, Sara、Salerno, Giuseppe
DOI:——
日期:——
Dixon; Kennedy, Journal of the Chemical Society, 1920, vol. 117, p. 76
作者:Dixon、Kennedy
DOI:——
日期:——
Discovery of a Potent and Selective Noncovalent Linear Inhibitor of the Hepatitis C Virus NS3 Protease (BI 201335)
作者:Montse Llinàs-Brunet、Murray D. Bailey、Nathalie Goudreau、Punit K. Bhardwaj、Josée Bordeleau、Michael Bös、Yves Bousquet、Michael G. Cordingley、Jiamin Duan、Pat Forgione、Michel Garneau、Elise Ghiro、Vida Gorys、Sylvie Goulet、Ted Halmos、Stephen H. Kawai、Julie Naud、Marc-André Poupart、Peter W. White
DOI:10.1021/jm100690x
日期:2010.9.9
C-Terminal carboxylic acid containing inhibitors of the NS3 protease are reported. A novel series of linear tripeptide inhibitors that are very potent and selective against the NS3 protease are described. A substantial contribution to the potency of these linear inhibitors arises from the introduction of a C8 substituent on the B-ring of the quinoline moiety found on the P2 of these inhibitors. The introduction of a CS methyl group results not only in a modest increase in the cell-based potency of these inhibitors but more importantly in a much better pharmacokinetic profile in rats as well. Exploration of C8-substitutions led to the identification of the bromo derivative as the best group at this position, resulting in a significant increase in the cell-based potency of this class of inhibitors. Structure activity studies on the C8-bromo derivatives ultimately led to the discovery of clinical candidate 29 (BI 201335), a very potent and selective inhibitor of genotypel NS3 protease with a promising PK profile in rats.
Doran, Journal of the Chemical Society, 1901, vol. 79, p. 910